Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rucaparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 15/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 9/20 | 0.65 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | TNKS | O95271 | 1/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | CDK1 | P06493 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | POLA1 | P09884 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.65 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.65 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rucaparib SCHEMBL22817574 | 1.00 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL17512178 | 1.00 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL30413070 | 0.83 | PARP1 (0.87) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL29351768 | 0.81 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL844585 | 0.81 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL29392034 | 0.80 | PARP1 (0.98) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL5746065 | 0.80 | PARP1 (0.98) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL844872 | 0.78 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL29379028 | 0.78 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL5747917 | 0.78 | PARP1 (0.90) | PARP1PARP2DYRK3TNKSPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2091 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-4676551-A1 | RADIATION SPACER HYDROGELS, METHODS OF FORMING, AND METHODS OF USE | Clearstream Technologies Limited (IE) | 2026-01-14 | — | — | EP | claimed |
| US-20260000689-A1 | TARGETING CREB-HEPARAN SULFATE-FGF PATHWAY FOR CANCER TREATMENT | UNIV SOUTH FLORIDA (US) | 2026-01-01 | — | — | US | claimed |
| US-20250255857-A1 | METHODS OF TREATING ANDROGEN RECEPTOR-INDEPENDENT PROSTATE CANCER | FOGHORN THERAPEUTICS INC. | 2025-08-14 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-20250197513-A1 | OSMR-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-19 | — | — | US | claimed |
| WO-2025111447-A1 | TREATMENT OF CANCER WITH DRUG COMBINATIONS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250129163-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | AKESO BIOPHARMA, INC. (CN) | 2025-04-24 | — | — | US | claimed |
| WO-2025080769-A1 | METHODS OF TREATING CANCER | FOGHORN THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| EP-4537108-A1 | ALLELIC IMBALANCE OF CHROMATIN ACCESSIBILITY IN CANCER IDENTIFIES CAUSAL RISK VARIANTS AND THEIR MECHANISMS | Dana-Farber Cancer Institute, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| WO-2022188832-A1 | PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | 中山康方生物医药有限公司 | 2022-09-15 | — | — | WO | claimed |
| WO-2022159624-A1 | LIQUID BIOPSY YIELD ENHANCEMENT | SINGHAL SEEMA (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022152290-A1 | NOVEL ANTI-GREMLIN1 ANTIBODIES | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2022-07-21 | — | — | WO | claimed |
| WO-2022155352-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES, INC. (US) | 2022-07-21 | — | — | WO | claimed |
| CN-114728994-A | Aryl phosphorus oxygen compound and application thereof | 成都地奥九泓制药厂 | 2022-07-08 | — | — | CN | claimed |
| US-11352362-B2 | Polymorph of rucaparib camsylate | SHANGHAI BEGREAT PHARMATECH (CN) | 2022-06-07 | — | — | US | claimed |
| WO-2022036024-A9 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3966782-A2 | METHODS FOR CHARACTERIZING AND TREATING A CANCER TYPE USING CANCER IMAGES | Tesaro, Inc. (US) | 2022-03-16 | — | — | EP | claimed |
| WO-2022046947-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF A VARIANT | GUARDANT HEALTH, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2022036024-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-17 | — | — | WO | claimed |